[go: up one dir, main page]

PE20191133A1 - Cristal de derivado de pirido[3,4-d]pirimidina o su solvato - Google Patents

Cristal de derivado de pirido[3,4-d]pirimidina o su solvato

Info

Publication number
PE20191133A1
PE20191133A1 PE2019001068A PE2019001068A PE20191133A1 PE 20191133 A1 PE20191133 A1 PE 20191133A1 PE 2019001068 A PE2019001068 A PE 2019001068A PE 2019001068 A PE2019001068 A PE 2019001068A PE 20191133 A1 PE20191133 A1 PE 20191133A1
Authority
PE
Peru
Prior art keywords
crystal
pyrid
refers
compound
solvate
Prior art date
Application number
PE2019001068A
Other languages
English (en)
Inventor
Hidetoshi Miyamoto
Tsuyoshi Mizuno
Gen Unoki
Yuki Miyazawa
Naoki Yajima
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of PE20191133A1 publication Critical patent/PE20191133A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Walking Sticks, Umbrellas, And Fans (AREA)

Abstract

SE REFIERE A UN CRISTAL DE UN COMPUESTO DE FORMULA (I) DONDE R1 ES H O UN GRUPO ALQUILO C1-C3; R2 ES H O UN GRUPO OXO; L ES UN ENLACE SIMPLE O UN GRUPO ALQUILENO C1-C3; X ES CH O N; EN DONDE EL CRISTAL DEL COMPUESTO 1-(6-((6-((1R)-1-HIDROXIETIL)-8-(ISOPROPILAMINO)PIRIDO[3,4-D]PIRIMIDIN-2-IL)AMINO)-3-PIRIDIL)PIPERAZIN-2-ONA EXHIBE PICOS EN ANGULOS DE DIFRACCION 2THETA IGUALES A 6.3°, 6.6°, 11.6°, 16.9° Y 20.0° EN UN ESPECTRO DE DIFRACCION DE RAYOS X DE POLVOS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHO CRISTAL TIENE UNA ACTIVIDAD INHIBIDORA DE CDK4/6 SIENDO UTIL EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ARTERIOSCLEROSIS, FIBROSIS PULMONAR, INFARTO CEREBRAL O CANCER
PE2019001068A 2016-11-28 2017-11-27 Cristal de derivado de pirido[3,4-d]pirimidina o su solvato PE20191133A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016229973 2016-11-28

Publications (1)

Publication Number Publication Date
PE20191133A1 true PE20191133A1 (es) 2019-09-02

Family

ID=62196036

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2023003166A PE20250397A1 (es) 2016-11-28 2017-11-27 Cristal de derivado de pirido[3,4-d]pirimidina o su solvato
PE2019001068A PE20191133A1 (es) 2016-11-28 2017-11-27 Cristal de derivado de pirido[3,4-d]pirimidina o su solvato

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2023003166A PE20250397A1 (es) 2016-11-28 2017-11-27 Cristal de derivado de pirido[3,4-d]pirimidina o su solvato

Country Status (31)

Country Link
US (1) US11261182B2 (es)
EP (1) EP3546456B1 (es)
JP (2) JP6745905B2 (es)
KR (1) KR102352637B1 (es)
CN (1) CN109996800B (es)
AU (1) AU2017364805B2 (es)
CA (1) CA3041854C (es)
CL (3) CL2019001420A1 (es)
CO (1) CO2019005513A2 (es)
CY (1) CY1125045T1 (es)
DK (1) DK3546456T3 (es)
EC (1) ECSP19037197A (es)
ES (1) ES2905437T3 (es)
HR (1) HRP20220065T1 (es)
HU (1) HUE057706T2 (es)
IL (1) IL266313B2 (es)
LT (1) LT3546456T (es)
MA (1) MA45887B1 (es)
MX (1) MX382362B (es)
MY (1) MY199852A (es)
NZ (1) NZ752990A (es)
PE (2) PE20250397A1 (es)
PH (1) PH12019500905A1 (es)
PL (1) PL3546456T3 (es)
PT (1) PT3546456T (es)
RS (1) RS63004B1 (es)
SI (1) SI3546456T1 (es)
TW (1) TWI755452B (es)
UA (1) UA124273C2 (es)
WO (1) WO2018097295A1 (es)
ZA (1) ZA201902828B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024006975A (es) * 2021-12-16 2024-08-27 Transthera Sciences Nanjing Inc Inhibidor de cdk9 y uso del mismo.
TW202521113A (zh) * 2023-09-27 2025-06-01 日商帝人製藥股份有限公司 類風濕性關節炎治療藥

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20063909B (en) 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
ATE433967T1 (de) * 2003-01-17 2009-07-15 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
NZ544609A (en) 2003-07-11 2008-07-31 Warner Lambert Co Isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
PT2331547E (pt) 2008-08-22 2014-10-29 Novartis Ag Compostos de pirrolopirimidina como inibidores de cdk
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
SG11201601138PA (en) * 2013-08-23 2016-03-30 Neupharma Inc Certain chemical entities, compositions, and methods
GB201403536D0 (en) * 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
TR201819419T4 (tr) * 2014-05-29 2019-01-21 Taiho Pharmaceutical Co Ltd Yeni tetrahidropiridopirimidin bileşiği veya tuzu.
BR112017005511A2 (pt) 2014-09-17 2018-08-14 Celgene Quanticel Res Inc inibidores da histona-desmetilase.
RU2695337C2 (ru) * 2015-05-29 2019-07-23 Тейдзин Фарма Лимитед ПРОИЗВОДНОЕ ПИРИДО[3,4-d]ПИРИМИДИНА И ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМАЯ СОЛЬ

Also Published As

Publication number Publication date
CY1125045T1 (el) 2023-03-24
RU2019116389A3 (es) 2021-04-16
LT3546456T (lt) 2022-03-10
CL2021001448A1 (es) 2022-01-14
CA3041854A1 (en) 2018-05-31
CL2021001447A1 (es) 2022-01-14
HRP20220065T1 (hr) 2022-04-15
HUE057706T2 (hu) 2022-05-28
JP7149980B2 (ja) 2022-10-07
IL266313B2 (en) 2023-12-01
MX2019005717A (es) 2019-08-12
EP3546456A4 (en) 2020-04-29
AU2017364805A2 (en) 2019-10-24
RU2019116389A (ru) 2020-11-30
MA45887B1 (fr) 2021-04-30
CL2019001420A1 (es) 2019-08-30
PT3546456T (pt) 2022-02-28
PE20250397A1 (es) 2025-02-11
WO2018097295A1 (ja) 2018-05-31
PL3546456T3 (pl) 2022-05-02
AU2017364805B2 (en) 2021-12-16
SI3546456T1 (sl) 2022-04-29
CN109996800A (zh) 2019-07-09
ES2905437T3 (es) 2022-04-08
JP6745905B2 (ja) 2020-08-26
MY199852A (en) 2023-11-25
RS63004B1 (sr) 2022-03-31
MA45887A1 (fr) 2020-11-30
CO2019005513A2 (es) 2019-07-31
NZ752990A (en) 2025-08-29
JPWO2018097295A1 (ja) 2019-06-24
TWI755452B (zh) 2022-02-21
IL266313B1 (en) 2023-08-01
IL266313A (en) 2019-06-30
ZA201902828B (en) 2022-05-25
UA124273C2 (uk) 2021-08-18
BR112019009448A2 (pt) 2019-07-30
US20210276997A1 (en) 2021-09-09
CA3041854C (en) 2025-05-13
CN109996800B (zh) 2021-11-19
JP2020121989A (ja) 2020-08-13
KR102352637B1 (ko) 2022-01-17
PH12019500905A1 (en) 2019-08-19
MX382362B (es) 2025-03-13
TW201833105A (zh) 2018-09-16
US11261182B2 (en) 2022-03-01
AU2017364805A1 (en) 2019-05-09
EP3546456B1 (en) 2022-01-12
DK3546456T3 (da) 2022-03-07
EP3546456A1 (en) 2019-10-02
KR20190067247A (ko) 2019-06-14
ECSP19037197A (es) 2019-06-30

Similar Documents

Publication Publication Date Title
CL2020003425A1 (es) Nuevos derivados heterocíclicos útiles como inhibidores de shp2 (divisional solicitud n° 201902698)
PH12020500529A1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
CY1124800T1 (el) Παραγωγο πυριδο[3,4-d]πυριμιδινης και φαρμακευτικως αποδεκτο αλας αυτου
MX2016015544A (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1.
MX2017007748A (es) Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirocina cinasa (trk).
MX2020007265A (es) Derivados de rapamicina.
CY1123850T1 (el) Παραγωγα ((πυριδιν-2-υλ)αμινο)πυριδο[3,4-d]πυριμιδινης και ((πυριδαζιν-3-υλ)αμινο)πυριδο[3,4-d]πυριμιδινης ως αναστολεις cdk4/6 για την αγωγη π.χ. της ρευματοειδους αρθριτιδας, της αρτηριοσκληρυνσης, της πνευμονικης ινωσης, του εγκεφαλικου εμφρακτου ή του καρκινου
MX374729B (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
PH12016501935A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015058163A3 (en) Heteromaromatic compounds useful for the treatment of prolferative diseases
PH12015502038A1 (en) 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
NZ715838A (en) Pyridines, pyrimidines, and pyrazines, as btk inhibitors and uses thereof
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
PE20151764A1 (es) Derivados de pirrolo[2,3-d]pirimidina
UY36244A (es) Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen
MX375372B (es) COMPOSICIONES DE COMPUESTOS DE MOLÉCULA PEQUEÑA Y USO DE LOS MISMOS COMO INHIBIDORES TrKA.
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
MD20160089A2 (ro) Analogi ai cortistatinului, sinteza şi utilizările acestora
GEP20227344B (en) Pyrimidine compound as jak kinase inhibitor
UA113470C2 (xx) Піримідинові та піридинові сполуки та їх застосування
EA201790016A1 (ru) АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K
DOP2015000214A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
CL2018000783A1 (es) Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
PE20191133A1 (es) Cristal de derivado de pirido[3,4-d]pirimidina o su solvato
WO2020036949A8 (en) Ask1 inhibiting agents